Teva Has Grand Ambitions In Respiratory Disease, With An Eye On Advair
This article was originally published in The Pink Sheet Daily
Executive Summary
Teva expects to more than double its respiratory sales to $2.4 billion by 2015, and launch multiple products in the timeframe, including an Advair-like product.